Amgen stops Phase III trial of ganitumab

Amgen Inc. (NASDAQ:AMGN) stopped the Phase III GAMMA trial in patients with metastatic adenocarcinoma of the pancreas after an interim analysis showed first-line treatment with ganitumab ( AMG 479) pl...